The Journal of Korean Obstetrics and Gynecology (대한한방부인과학회지)

The Society of Korean Medicine Obstetrics and Gynecology (대한한방부인과학회)
권호 표지
DOI QR코드

DOI QR Code

Recent Studies of Breast Cancer in Traditional Chinese Medicine Journals

중의학 논문에 나타난 유방암의 연구 동향에 대한 고찰 - 중의학 논문을 중심으로 -

  • Jerng, Ui-Min (Dept. of Oriental Internal medicine, College of Oriental medicine, Kyung Hee University) ;
  • Jeong, Jong-Soo (Dept. of Oriental Internal medicine, College of Oriental medicine, Kyung Hee University) ;
  • Park, Jae-Woo (Dept. of Oriental Internal medicine, College of Oriental medicine, Kyung Hee University) ;
  • Jung, Hyun-Sik (M.u Integrative Cancer Center, Kyung Hee University East-West Neo Medical Center) ;
  • Yoon, Seong-Woo (Dept. of Oriental Internal medicine, College of Oriental medicine, Kyung Hee University)
  • 정의민 (경희대학교 한의과대학 내과학교실) ;
  • 정종수 (경희대학교 한의과대학 내과학교실) ;
  • 박재우 (경희대학교 한의과대학 내과학교실) ;
  • 정현식 (경희대학교 동서신의학병원 M.u 통합암센터) ;
  • 윤성우 (경희대학교 한의과대학 내과학교실)
  • Published : 2009.02.27
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The purpose of this study is to research trends in the study of breast cancer in Traditional Chinese Medicine (TCM) and to establish the further direction for its study. Methods: We reviewed TCM papers published in the last 29 years (1979-2008). Results: 1. We researched 49 papers and the patterns of study were as follows: in vitro studies were 27 papers (55.1%), in vivo studies were 9 papers (18.4%) and clinical studies were 19 papers (38.8%). 2. In vitro studies on breast cancer research in TCM were focused on cytotoxicity (17 papers) and apoptosis (8 papers). Most of in vivo studies (6 papers) were done for the purpose of inducing growth suppression of tumor cell after administration of the test drug. Each drug acted on this effect through various types of mechanism. 3. Unlike in vitro and in vivo studies, clinical studies on growth suppression of tumor cell were rare (4 papers). Most of the studies were focused on reduction of side effect of chemotherapy or synergistic effect with chemotherapy (7 papers), immune regulation (7 papers), and improvement of quality of life (6 papers). 4. Among the treatment method we reviewed, 'Runing Ⅱ(Ⅱ號方)' was the only medication that further studied as clinical trial after experimental study. 5. Since almost all studies have defects like poorly designed model or insufficient data description, it was difficult to make any definite conclusion about these studies. Conclusion: More subsequent clinical studies based on experimental study will be needed afterwards. Strict and high-level study design with detailed description will be needed in further study.

Keywords

References

  1. Parkin DM et al. Global cancer statistics 2002. CA Cancer J Clin. 2005;55(2): 74-108. https://doi.org/10.3322/canjclin.55.2.74
  2. Korea Central Cancer Registry. 2002 Annual Report of the Korea Central Cancer Registry. Seoul: Ministry of Health and Welfare. 2003.
  3. Anthony SF et al. Harrison's Principals of Internal Medicine, 17th Edition. New York: McGraw-Hill Medical. 2008.
  4. Ries LAG et al. SEER Cancer Statistics Review 1975-2005. Bethesda: National Cancer Institute. 2008.
  5. Gerber B et al. Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review. Breast Cancer Res Treat. 2006;95(3):199-209. https://doi.org/10.1007/s10549-005-9005-y
  6. 韓月恒 等. 水飛薊素對乳腺癌细胞系的 作用及其机制研究. 中草藥. 2003;34(3): 238-241.
  7. 張曉麗 等, 延胡索索乙素逆轉多藥耐藥性人乳腺癌細胞MCF-7. 中藥藥理与臨床. 2005;21(6):19-21.
  8. 高志捷 等. 薯蓣皂苷体外抑制腫瘤細胞 增殖的研究. 中國中医藥信息雜志. 2005; 12(7):33-34.
  9. 張静 等. 香加皮乙酸乙酯提取物誘導人乳腺癌MCF-7細胞凋亡的研究. 腫瘤. 2006; 26(5):418-421.
  10. 陳曉蕾, 湯立建, 李慶林. 淫羊藿, 秦皮醇提取物体外抗乳腺癌細胞增殖的研究. 中國藥房. 2007;18(15):1124-1127.
  11. 尹春萍 等. 紅三叶總异黄酮對人乳腺癌MCF-7細胞增殖和凋亡的影響. 中草藥. 2007;38(2):232-234.
  12. 劉東颖 等. 冬虫夏草對乳腺癌細胞凋亡的誘導及相關基因表達的調控. 天津医科大學學報. 2007;13(2):206-209.
  13. 劉東颖. 冬虫夏草誘導乳癌細胞MCF-7凋亡的實驗研究. 河北中医. 2007;29(1): 66-68.
  14. 尹春萍 等. 猫爪草皂苷抑制乳腺癌的机制研究. 中國医院藥學雜志. 2008; 28(2):93-96.
  15. 河福金 等. 金雀黄素和大豆黄酮對人乳腺癌細胞系体外增殖作用的影響. 北京中医藥大學學報. 2002;25(1):22-25.
  16. 吳雪卿 等. 中藥乳宁II号對人乳腺癌 MCF-7細胞株体内外生長的影響. 中國中医藥科技 2000;7(4):211-212.
  17. 韓炯 等. 葡萄籽提取物原花青素誘導乳腺癌MCF-7細胞脱落凋亡. 中草藥. 2003;34(8):722-725.
  18. 張文卿 等. 中藥R1對耐阿霉素人乳腺癌細胞系（MCF7adr）多藥耐受的逆轉 作用. 中藥藥理与臨床. 1994;5:16-21.
  19. 郭偉劍 等. 康莱特誘導具多藥耐藥表 型的人乳腺癌細胞MCF7adr凋亡及周期阻滯的研究. 中國中西医結合雜志. 2001;21:123-125.
  20. 河福金 等. 金雀异黄素對人乳腺癌細胞体外生長的抑制作用. 中國中藥雜志. 2002;27(12):936-939.
  21. 宋士一, 馬宏. 大蒜成分DADS抑制人類乳腺癌細胞MDA-MB-231的惡性表 型及环氧化酶-2的基因表達. 實用癌症雜志. 2007;22(1):9-12.
  22. 朱國旗 等. 黄芩苷誘導人乳腺癌細胞株MDA-MB-231凋亡作用的研究. 安徽中医學院學報. 2008;27(2):20-23.
  23. 朱曉音 等. 当歸提取物對PC3,HeLa, MDA-MB-435腫瘤細胞增殖的影響. 山東中医雜志. 2007;26(11):776-778.
  24. 戚玮琳 等. 紅景天抑制乳腺癌血管新生的作用及其机制. 上海中医藥雜志. 2007;41(7):62-65.
  25. 闕華發 等. 乳宁 II 号對人乳腺癌MDAMB-435細胞株生長轉移的影響. 中國中医基础医學雜志. 2002;8(7):32-34.
  26. 朱君榮 等. 人参皂苷-Rh_2對人乳腺癌T47D細胞的生長抑制作用及對 Caspase-3表達的影響. 中國臨床藥理學与治療學. 2007;12(6):630-634.
  27. 趙丕文 等. 异補骨脂素和蜕皮甾酮對 人乳腺癌T47D細胞增殖及ER亞型表達的影響. 北京中医藥大學學報. 2007; 30(4):242-245.
  28. 孫斌, 瞿偉菁, 柏忠江. 蒺藜皂苷對乳腺癌細胞Bcap-37的体外抑制作用. 中藥材. 2003;26(2):104-106.
  29. 馮正權 吳良村. 安体优主要成分体外抑制BCAP37細胞生長的實驗研究. 浙江中医學院學報. 2003;27(5):53-54.
  30. 章平 等. 沙棘籽渣黄酮誘導人乳腺癌 細胞凋亡相關基因的表達譜變化. 癌症. 2005;24(4):454-460.
  31. 徐貴發 等. 麦胚黄酮類提取物對人乳腺癌細胞BCap-37的体外抑制作用. 衛生研究. 1999;28(3):151-152.
  32. 趙秀蘭 等. Genistein對人乳腺癌細胞株BCaP-37的体外抑制作用. 山東大學學報(医學版). 2002;40(4):373-375.
  33. 薛美蘭 等. 牛磺酸抑制二甲基苯蒽誘發大鼠乳腺癌及其机制研究. 營養學報. 2008;30(1):57-60.
  34. 谷俊朝 等. 黄芪多糖對TA2小鼠乳腺癌MA-891移植瘤生長及HSP70表達的影響. 中華腫瘤防治雜志. 2006;20(4): 1534-1537.
  35. 陳信義, 高志捷, 王玉芝. 薯蓣皂苷抗移植性小鼠乳腺癌作用的研究. 中國中医藥信息雜志. 2005;12(5):23-24.
  36. 陳前軍 等. 乳宁 II 号方對小鼠Ca761乳腺癌移植瘤細胞周期及p53和ras表達的影響. 中西医結合學報. 2005;3(3): 225-228.
  37. 吳雪卿 等. 乳宁 II 号對MCF-7移植瘤的抑瘤作用及對乳腺癌相關蛋白的影響. 中國中西医結合外科雜志. 2004; 10(2):99-102.
  38. 沈健, 姚榛祥. 中藥CY-1号對外源性雌激素致乳腺癌危險因素的阻斷作用. 中國中西医結合雜志. 2001;21:128-130.
  39. 劉鹏 等. 参麥注射液促進乳腺癌患者術后恢复的臨床觀察. 中國中西医結合雜志. 2000;20(5):328-329.
  40. 代志軍 等. 参芪扶正注射液在乳腺癌新輔助化療中的療效及不良反應的臨床觀察. 藥物不良反應雜志. 2007;9(1): 10-14.
  41. 陳芳, 林紅. 参芪扶正注射液輔助乳癌化療的療效觀察. 海峡藥學. 2007;19(12): 75-76.
  42. 黄智芬 等. 参芪扶正注射液聯合化療治療晚期乳腺癌30例臨床觀察. 中國中西医結合雜志. 2008;28(2):152-154.
  43. 李洪胜 等. 中医扶正培本治療對乳腺癌新輔助化療患者免疫功能的影響. 臨床腫瘤學雜志. 2006;11(11):851-857.
  44. 勞溢權. 苦参域注射液預防乳腺癌化療 后肝功能損害效果觀察. 中藥材. 2005; 28(8):735-737.
  45. 劉海濤, 侯俊明, 馬曉萍. 苦参素注射液配合術后化療治療乳腺癌臨床觀察. 西部医學. 2008;20(1):96-97.
  46. 劉胜 等. 乳移平抗乳腺癌術后复發轉移的臨床研究. 中西医結合學報. 2007; 5(2):147-149.
  47. 張瑾, 吳咸中, 伍孝先. 益气養血顆粒對絶經后乳腺癌患者内分泌功能的調節作用. 中國中西医結合外科雜志. 1999; 5(6):335-337.
  48. 王怀璋. 中藥配合化療治療晚期乳腺癌骨轉移疼痛53例. 遼宁中医雜志. 2001; 28(40):211-212.
  49. 梁少華, 李敏江, 李廷冠. 升血和中湯防治乳腺癌術后化療毒副反應臨床觀察. 广西中医藥. 2002;25(4):8-12.
  50. 翁永强 等. 扶正祛邪法改善乳腺癌患者化療毒副作用的臨床觀察. 上海中医藥大學學報. 2003;17(3):28-31.
  51. 万華 等. “乳癌術后方”對乳腺癌患者生活質量影響的臨床研究. 上海中医藥雜志. 2004;38(9):28-31.
  52. 程亦勤. 唐漢鈞教授治療乳腺癌手術后傷口不愈的經驗. 中西医結合學報. 2005; 3(3):238-239.
  53. 沈曄華, 宋明志, 黄雯霞. 中西医結合治療71例乳腺癌術后患者的療效分析. 中西医結合學報. 2003;1(1):30-31.
  54. 司徒紅林 等. 中藥癌复康對乳腺癌術后化療患者生存質量的影響. 广州中医藥大學學報. 2005;22(1):26-29.
  55. 李洪胜 等. 扶正培本法對乳腺癌患者樹突狀細胞的影響研究. 中藥材. 2007;34(7):377-380.
  56. 聞小娟. 消腫散治乳腺癌60例臨床觀察. 遼宁中医雜志. 2007;34(7):909-910.
  57. 張莉 等. 扶正消瘤湯對乳腺癌患者生 活質量的影響. 現代中西医結合雜志. 2007;16(18):2494-2573.
  58. Burdall SE et al. Breast cancer cell lines, friend or foe? Breast Cancer Research. 2003;5(2):89-95. https://doi.org/10.1186/bcr577
  59. Dickson RB et al. Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res. 1986;46(4 Pt 1) :1707-1713.
  60. Mukhopadhyay R, Theriault RL, Price JE. Increased levels of alpha6 integrins are associated with the metastatic phenotype of human breast cancer cells. Clin Exp Metastasis. 1999;17(4):325-332.
  61. Thompson EW et al. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol. 1992;150:534-544. https://doi.org/10.1002/jcp.1041500314
  62. Bai J et al. Retroviral vector containing human p16 gene and its inhibitory effect on Bcap-37 breast cancer cells. Chin Med J. 2001;114(5): 497-501.
  63. Biscardi JS, Belsches AP, Parsons SJ. Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol Carcinog 1998;21(4):261-72. https://doi.org/10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N
  64. Szollosi J et al. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res. 1995;55(22):5400-5407.
  65. Jadad AR et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials. 1996;17(1):1-12. https://doi.org/10.1016/0197-2456(95)00134-4